A Cohort Study of Antihyperglycemic Medication Exposure and Gastric Cancer Risk

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Feb 9

PMID 32033451

Citations 11

Authors

Audrius Dulskas

Ausvydas Patasius

Auguste Kaceniene

Donata Linkeviciute-Ulinskiene

Lina Zabuliene

Giedre Smailyte

Affiliations

Soon will be listed here.

Abstract

We assessed gastric cancer risk in type 2 diabetes mellitus patients. Gastric cancer patients with diabetes between 2001-2012 were identified. Four groups were analysed: combination therapy with metformin users; insulin and other medication users; metformin and insulin users; and sulfonylurea users. Standardised incidence ratios (SIRs) for gastric cancers as a ratio of the observed number of cancer cases in people with diabetes to the expected number of cancer cases in the underlying general population were calculated. A total of 99,992 patients with diabetes were analysed and 337 gastric cancer cases in patients with diabetes were observed when compared to the expected number of 400.54 gastric cancer cases, according to the cancer rates of the general population (SIR 0.84, 95% confidence interval (CI): 0.76-0.94). Lower risk of gastric cancer was found both in male and female patients with diabetes, however, risk among females was insignificantly lower. Higher gastric cancer risk was found in the group of diabetic patients treated with sulfonylureas (SIR 1.31, 95% CI: 1.04-1.65) and significantly lower risk than expected from the general population was found in the group of metformin users (SIR 0.75, 95% CI: 0.66-0.86). Type 2 diabetes mellitus was not associated with increased risk of gastric cancer. Metformin might decrease the risk of gastric cancer in patients with diabetes, while sulfonylureas may increase gastric cancer risk.

Citing Articles

Metformin in combination with chemotherapy increases apoptosis in gastric cancer cells and counteracts senescence induced by chemotherapy.

Vazquez-Ibarra K, Sanchez Lopez J, Pineda Razo T, Cruz Lozano J, Ortiz-Tamayo B, Palafox-Mariscal L Oncol Lett. 2024; 28(4):457.

PMID: 39114572 PMC: 11304395. DOI: 10.3892/ol.2024.14590.

The causal relationship between anti-diabetic drugs and gastrointestinal disorders: a drug-targeted mendelian randomization study.

Ju M, Deng T, Jia X, Gong M, Li Y, Liu F Diabetol Metab Syndr. 2024; 16(1):141.

PMID: 38918852 PMC: 11201305. DOI: 10.1186/s13098-024-01359-z.

Diabetes and gastric cancer incidence and mortality in the Asia Cohort Consortium: A pooled analysis of more than a half million participants.

De la Torre K, Song M, Abe S, Rahman M, Islam M, Saito E J Diabetes. 2024; 16(6):e13561.

PMID: 38751364 PMC: 11096812. DOI: 10.1111/1753-0407.13561.

Metformin: A Dual-Role Player in Cancer Treatment and Prevention.

Galal M, Al-Rimawi M, Hajeer A, Dahman H, Alouch S, Aljada A Int J Mol Sci. 2024; 25(7).

PMID: 38612893 PMC: 11012626. DOI: 10.3390/ijms25074083.

Diabetes Mellitus and Gastric Cancer: Correlation and Potential Mechanisms.

Wang L, Zhang Z J Diabetes Res. 2023; 2023:4388437.

PMID: 38020199 PMC: 10653978. DOI: 10.1155/2023/4388437.

References

Hsieh M, Lee T, Cheng S, Tu S, Yen M, Tseng C . The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res. 2012; 2012:413782. PMC: 3374948. DOI: 10.1155/2012/413782. View

Hendriks A, Schrijnders D, Kleefstra N, de Vries E, Bilo H, Jalving M . Sulfonylurea derivatives and cancer, friend or foe?. Eur J Pharmacol. 2019; 861:172598. DOI: 10.1016/j.ejphar.2019.172598. View

Chang C, Lin J, Wu L, Lai M, Chuang L . Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012; 97(7):E1170-5. DOI: 10.1210/jc.2012-1162. View

Chiu C, Huang C, Chen Y, Chen T, Liang Y, Lin S . Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan. Intern Med. 2013; 52(9):939-46. DOI: 10.2169/internalmedicine.52.8276. View

Cheung K, Chan E, Wong A, Chen L, Seto W, Wong I . Metformin Use and Gastric Cancer Risk in Diabetic Patients After Helicobacter pylori Eradication. J Natl Cancer Inst. 2018; 111(5):484-489. DOI: 10.1093/jnci/djy144. View

. Introduction: . Diabetes Care. 2018; 42(Suppl 1):S1-S2. DOI: 10.2337/dc19-Sint01. View

Kim H, Lee S, Chun K, Jeon J, Han S, Kim D . Metformin reduces the risk of cancer in patients with type 2 diabetes: An analysis based on the Korean National Diabetes Program Cohort. Medicine (Baltimore). 2018; 97(8):e0036. PMC: 5841986. DOI: 10.1097/MD.0000000000010036. View

Tseng C . Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus. Aging (Albany NY). 2016; 8(8):1636-49. PMC: 5032687. DOI: 10.18632/aging.101019. View

Dulskas A, Patasius A, Linkeviciute-Ulinskiene D, Zabuliene L, Smailyte G . A cohort study of antihyperglycemic medication exposure and survival in patients with gastric cancer. Aging (Albany NY). 2019; 11(17):7197-7205. PMC: 6756873. DOI: 10.18632/aging.102245. View

10.

Guggenheim D, Shah M . Gastric cancer epidemiology and risk factors. J Surg Oncol. 2012; 107(3):230-6. DOI: 10.1002/jso.23262. View

11.

Lee M, Hsu C, Wahlqvist M, Tsai H, Chang Y, Huang Y . Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011; 11:20. PMC: 3031263. DOI: 10.1186/1471-2407-11-20. View

12.

Tseng C, Tseng F . Diabetes and gastric cancer: the potential links. World J Gastroenterol. 2014; 20(7):1701-11. PMC: 3930970. DOI: 10.3748/wjg.v20.i7.1701. View

13.

Higurashi T, Nakajima A . Metformin and Colorectal Cancer. Front Endocrinol (Lausanne). 2018; 9:622. PMC: 6205961. DOI: 10.3389/fendo.2018.00622. View

14.

Chen Y, Du L, Li L, Ma J, Geng X, Yao X . Cancer risk of sulfonylureas in patients with type 2 diabetes mellitus: A systematic review. J Diabetes. 2016; 9(5):482-494. DOI: 10.1111/1753-0407.12435. View

15.

Chen Y, Cheng K, Lai S, Tsai I, Lin C, Sung F . Diabetes and risk of subsequent gastric cancer: a population-based cohort study in Taiwan. Gastric Cancer. 2012; 16(3):389-96. DOI: 10.1007/s10120-012-0197-7. View

16.

Hay N . The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 2005; 8(3):179-83. DOI: 10.1016/j.ccr.2005.08.008. View

17.

Kim Y, Kim S, Cho S, Park J, Choi I, Lee Y . Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort study. Aliment Pharmacol Ther. 2014; 39(8):854-63. DOI: 10.1111/apt.12660. View

18.

Bowker S, Majumdar S, Veugelers P, Johnson J . Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29(2):254-8. DOI: 10.2337/diacare.29.02.06.dc05-1558. View

19.

Karlstad O, Starup-Linde J, Vestergaard P, Hjellvik V, Bazelier M, Schmidt M . Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. Curr Drug Saf. 2013; 8(5):333-48. PMC: 3899599. DOI: 10.2174/15680266113136660067. View

20.

Miao Z, Xu H, Xu Y, Wang Z, Zhao T, Song Y . Diabetes mellitus and the risk of gastric cancer: a meta-analysis of cohort studies. Oncotarget. 2017; 8(27):44881-44892. PMC: 5546528. DOI: 10.18632/oncotarget.16487. View